Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
36
36 articles ont été cités au moins 36fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
h-index
Total citations reçues
8 627
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
149
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
76
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Institut Gustave Roussy · Issy Media (France) · International and European Law School
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma
2023ArticleClinical Nuclear Medicine
Dissemination patterns of Hodgkin lymphoma using a probability network model based on [(18)F]-FDG PET/CT
2023ArticleEuropean Journal of Nuclear Medicine and Molecular Imaging
Le lymphome de Hodgkin : stratégies thérapeutiques actuelles et futures
2018ArticleBulletin du Cancer
Prognosis value of baseline total metabolic tumor volume (TMTV) in advanced Hodgkin lymphoma (HL) : Ancillary study of AHL2011 LYSA trial
2016CongrèsAnnual Congress of the European-Association-of-Nuclear-Medicine (EANM)
Combined Linkage and Association Studies Show that HLA Class II Variants Control Levels of Antibodies against Epstein-Barr Virus Antigens
2014ArticlePLoS ONE
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
2013ArticleHaematologica
Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study
2012ArticleJournal of Clinical Oncology
Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study
2012ArticleJournal of Clinical Oncology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Blood · 2010
Abstract We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years, with a median follow-up time of 10 years. Clinical event information was updated in all living patients (with the exception of 3 patients) in 2009. Survival end points were improved in patients treated with R-CHOP: the 10-year progression-free survival was 36.5%, compared with 20% with CHOP alone, and the 10-year overall survival was 43.5% compared with 27.6%. The same risk of death due to other diseases, secondary cancers, and late relapses was observed in both study arms. Relapses occurring after 5 years represented 7% of all disease progressions. The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP. Our findings underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy.
Lancet (London, England) · 2011
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients who need reduced or more intensive treatments. Methods We performed a randomized trial to evaluate treatment adaptation on the basis of early PET (ePET) after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untreated—according to European Organisation for Research and Treatment of Cancer criteria favorable (F) and unfavorable (U)—stage I and II HL. The standard arm consisted of ABVD followed by involved-node radiotherapy (INRT), regardless of ePET result. In the experimental arm, ePET-negative patients received ABVD only (noninferiority design), whereas ePET-positive patients switched to two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) and INRT (superiority design). Primary end point was progression-free survival (PFS). Results Of 1,950 randomly assigned patients, 1,925 received an ePET—361 patients (18.8%) were positive. In ePET-positive patients, 5-year PFS improved from 77.4% for standard ABVD + INRT to 90.6% for intensification to BEACOPPesc + INRT (hazard ratio [HR], 0.42; 95% CI, 0.23 to 0.74; P = .002). In ePET-negative patients, 5-year PFS rates in the F group were 99.0% versus 87.1% (HR, 15.8; 95% CI, 3.8 to 66.1) in favor of ABVD + INRT; the U group, 92.1% versus 89.6% (HR, 1.45; 95% CI, 0.8 to 2.5) in favor of ABVD + INRT. For both F and U groups, noninferiority of ABVD only compared with combined modality treatment could not be demonstrated. Conclusion In stage I and II HL, PET response after two cycles of ABVD allows for early treatment adaptation. When ePET is positive after two cycles of ABVD, switching to BEACOPPesc + INRT significantly improved 5-year PFS. In ePET-negative patients, noninferiority of ABVD only could not be demonstrated: risk of relapse is increased when INRT is omitted, especially in patients in the F group.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Leukemia & lymphoma · 2024 · Journal Article
Rossetti S, Juul SJ, van der Kaaij MAE, Fortpied C, et al.
Journal of cancer survivorship : research and practice · 2024 · Journal Article
Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, et al.
Acta oncologica (Stockholm, Sweden) · 2023 · Journal Article
Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, et al.
La Revue du praticien · 2023 · English Abstract
Fermé C
European journal of nuclear medicine and molecular imaging · 2023 · Journal Article
Mouheb M, Pierre-Jean M, Fermé C, Devillers A, et al.
Cancer medicine · 2020 · Journal Article
Saleh K, Michot JM, Schernberg A, Lazarovici J, et al.
Bulletin du cancer · 2018 · Journal Article
Turpin A, Michot JM, Kempf E, Mazeron R, et al.
European journal of cancer (Oxford, England : 1990) · 2017 · Journal Article
Michot JM, Lazarovici J, Ghez D, Danu A, et al.
European journal of nuclear medicine and molecular imaging · 2017 · Journal Article
Lazarovici J, Terroir M, Arfi-Rouche J, Michot JM, et al.
The Lancet. Haematology · 2017 · Clinical Trial, Phase II
Peyrade F, Bologna S, Delwail V, Emile JF, et al.
Bulletin du cancer · 2016 · Journal Article
Biya J, Stoclin A, Dury S, Le Pavec J, et al.
Haematologica · 2015 · Journal Article
Lazarovici J, Dartigues P, Brice P, Obéric L, et al.
European journal of cancer (Oxford, England : 1990) · 2015 · Journal Article
Michot JM, Mazeron R, Danu A, Lazarovici J, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014 · Clinical Trial, Phase II
Fruchart C, Tilly H, Morschhauser F, Ghesquières H, et al.
International journal of radiation oncology, biology, physics · 2014 · Journal Article
Girinsky T, Aupérin A, Ribrag V, Elleuch M, et al.
PloS one · 2014 · Journal Article
Pedergnana V, Syx L, Cobat A, Guergnon J, et al.
Cytokine · 2013 · Journal Article
Ghesquières H, Maurer MJ, Casasnovas O, Ansell SM, et al.
Haematologica · 2013 · Journal Article
Van Den Neste E, Casasnovas O, André M, Touati M, et al.
International journal of radiation oncology, biology, physics · 2012 · Evaluation Study
Girinsky T, Paumier A, Ferme C, Hanna C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012 · Journal Article
van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, et al.
Haematologica · 2011 · Journal Article
Harel S, Fermé C, Poirot C
La Revue du praticien · 2010 · English Abstract
Mounier N, Fermé C
The Journal of infectious diseases · 2009 · Journal Article
Besson C, Amiel C, Le-Pendeven C, Plancoulaine S, et al.
Haematologica · 2009 · Journal Article
van der Kaaij MA, Heutte N, van Echten-Arends J, Raemaekers JM, et al.
Cancer · 2009 · Journal Article
Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008 · Clinical Trial, Phase II
Morschhauser F, Brice P, Fermé C, Diviné M, et al.
European journal of haematology · 2021 · Journal Article
Abdayem P, Ibrahim N, El Dakdouki Y, Willekens C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014 · Clinical Trial, Phase III
Molina TJ, Canioni D, Copie-Bergman C, Recher C, et al.
Blood · 2014 · Clinical Trial, Phase III
International journal of radiation oncology, biology, physics · 2018 · Equivalence Trial
Thomas J, Fermé C, Noordijk EM, Morschhauser F, et al.
European journal of cancer (Oxford, England : 1990) · 2017 · Journal Article
Fermé C, Thomas J, Brice P, Casasnovas O, et al.
Clinical nuclear medicine · 2024 · Journal Article
Mouheb M, Pierre-Jean M, Devillers A, Fermé C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012 · Journal Article
van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, et al.
The Lancet. Oncology · 2009 · Journal Article
Heutte N, Flechtner HH, Mounier N, Mellink WA, et al.
Medicine · 2014 · Journal Article
London J, Grados A, Fermé C, Charmillon A, et al.
Sarkozy C, Seymour JF, Ferme C, Caballero D, et al.
Transfusion · 2013 · Journal Article
Lefrère F, Bastit-Barrau D, Hequet O, Bourin P, et al.
Haematologica · 2013 · Comparative Study
Bachy E, Houot R, Morschhauser F, Sonet A, et al.
The Lancet. Oncology · 2013 · Clinical Trial, Phase III
Delarue R, Tilly H, Mounier N, Petrella T, et al.
Haematologica · 2011 · Clinical Trial, Phase II
Fitoussi O, Belhadj K, Mounier N, Parrens M, et al.
Lancet (London, England) · 2011 · Clinical Trial, Phase III
Salles G, Seymour JF, Offner F, López-Guillermo A, et al.
Lancet (London, England) · 2011 · Clinical Trial, Phase III
Récher C, Coiffier B, Haioun C, Molina TJ, et al.
Leukemia & lymphoma · 2011 · Journal Article
Heutte N, Haioun C, Feugier P, Coiffier B, et al.
Blood · 2010 · Comparative Study
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, et al.
Cancer · 2010 · Clinical Trial, Phase II
Morschhauser F, Mounier N, Sebban C, Brice P, et al.
Cancer · 2009 · Clinical Trial, Phase II
Ribrag V, Gisselbrecht C, Haioun C, Salles G, et al.
Blood · 2008 · Journal Article
Salles G, Mounier N, de Guibert S, Morschhauser F, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017 · Clinical Trial, Phase III
André MPE, Girinsky T, Federico M, Reman O, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016 · Clinical Trial, Phase III
Carde P, Karrasch M, Fortpied C, Brice P, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014 · Journal Article
Raemaekers JM, André MP, Federico M, Girinsky T, et al.
Haematologica · 2013 · Clinical Trial, Phase II
Ribrag V, Caballero D, Fermé C, Zucca E, et al.
The Lancet. Oncology · 2009 · Journal Article
Heutte N, Flechtner HH, Mounier N, Mellink WA, et al.